Organization
Wuerzburg University Hospital
7 clinical trials
Clinical trial
Prednisolone and Vitamin B1, B6, and B12 in Patients With Post-COVID-19-Syndrome (PC19S) - a Randomized Controlled Trial in Primary CareStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Autologous Dendritic Cells and Metronomic Cyclophosphamide in Combination With Checkpoint Blockade for Relapsed High-Grade Gliomas in Children and AdolescentsStatus: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIVStatus: Active (not recruiting), Estimated PCD: 2016-09-01
Clinical trial
An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With Xlinked Hypophosphatemia (XLH) in GERmany - BurGERStatus: Completed, Estimated PCD: 2023-03-17
Clinical trial
The Influence of Trained Immunity in COVID-19 Vaccinated IndividualsStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd Prior to and Following Auto-SCT in Newly Diagnosed Multipe Myeloma and Subsequent Maintenance With Elotuzumab and Lenalidomide Versus Single-Agent Lenalidomide- A Phase III Study by DSMMStatus: Active (not recruiting), Estimated PCD: 2029-08-01
Clinical trial
A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2025-12-01